NetraMark's AI Significantly Outperforms ChatGPT, DeepSeek and Traditional Machine Learning in Clinical Trial Subpopulation Discovery, Offers New Path for Trial Success
Globenewswire·2025-06-23 20:30
TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials has released a new preprint on arXiv demonstrating that its flagship AI platform, NetraAI, has substantially outperformed leading large language models, DeepSeek and ChatGPT. NetraAI also outperformed traditional machine learning techniques in identifying clinically meaningful patient ...